Curated news and analysis on clinical trials, drug approvals, and medical research.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
Measles cases are reappearing across the United States, challenging health systems unprepared for a disease declared eliminated in 2000. Clinical leaders must ensure rapid identification, isolation protocols, and vaccination strategies to prevent outbreaks.
Proteolysis-targeting chimeras (PROTACs) are advancing from experimental to clinical-stage cancer therapies, with first candidates entering Phase III trials. The technology degrades target proteins rather than blocking them, offering new options for previously undruggable targets.
Agentic AI models are streamlining oncology clinical trial design and reducing phase II to III failure risk. Separately, Aethlon Medical progresses its Hemopurifier device trial in Australia with strong safety data and accelerated patient recruitment.
The FDA is set to make decisions on four drug applications in April 2026, including Orca-T for hematological malignancies, orforglipron for obesity, sparsentan for kidney disease, and a doravirine/islatravir combination for HIV-1.
CellProthera plans to launch a Phase III trial of its ProtheraCytes stem cell therapy for heart failure patients in Q1 2027, enrolling 300-400 patients across 50 sites. The company acquired a transendocardial catheter from Celyad Oncology for €5 million to enable precise delivery of the therapy.
Diacerein, an anthraquinone derivative, shows promise as a disease-modifying agent in rheumatoid arthritis through its anti-inflammatory and chondroprotective actions, with combination therapy appearing to enhance therapeutic benefits.
Mayo Clinic is pursuing two distinct nanoparticle-based cancer treatments: milk-derived nanoparticles for targeted gene therapy in bile duct cancer, and magnetic nanoparticle hyperthermia for metastatic solid tumors.
The FDA issued a complete response letter rejecting Aldeyra Therapeutics' reproxalap for dry eye disease, marking the third rejection in three years due to inconsistent trial results and lack of substantial evidence of efficacy.
The American Psychiatric Association will include biomarkers in the next DSM edition, though such markers remain unvalidated for routine clinical use. Research has spanned decades with limited adoption despite potential to guide treatment selection.
The FDA has expanded approval of GSK's Arexvy RSV vaccine to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease, based on phase 3b trial data showing noninferior immune response.
Mayo Clinic researchers found that Brigatinib, an FDA-approved lung cancer drug, can block survival pathways in ovarian cancer cells when combined with PARP inhibitors, potentially overcoming treatment resistance.
CAR T-cell therapy demonstrates near-98% response rates in multiple myeloma trials, but only 2.6% of eligible patients receive treatment. Black patients face substantially lower access, with structural and institutional barriers limiting availability of the specialized therapy.
New research shows patients on GLP-1 drugs may need to delay endoscopy procedures due to retained gastric contents, while a Cleveland Clinic study found 45% of obesity patients maintained weight loss one year after stopping the medications.
Over 25 companies are developing 30+ therapies for celiac disease, with recent positive trial results and FDA Fast Track designation. A new blood test using T-cell receptor sequencing may enable noninvasive diagnosis and monitoring.
Prognica Labs and NextGen Immuno Therapeutics announced a strategic partnership to advance AI-powered immune diagnostics and personalized medicine across the GCC, India, and the United States, targeting oncology, transplant medicine, and autoimmune disorders.
Recent research identifies novel genetic causes for rare movement and neurodegenerative disorders, including CD99L2 variants in spastic ataxia, PPP2R5C as an Alzheimer's biomarker, and toxic polyglycine proteins in GGC repeat expansion diseases.
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Weill Cornell Medicine has launched an enterprise-wide AI to Advance Medicine initiative featuring a bimonthly lecture series, grant program, and new website to support safe and effective artificial intelligence use across research, education, and clinical care.
Roche deployed 2,176 new NVIDIA Blackwell GPUs, bringing its total above 3,500 chips across on-premise and cloud infrastructure. The expansion follows Eli Lilly's 1,016-GPU supercomputer launch and Recursion's 504-GPU system unveiled in 2024.
